Drug intelligence / Profile preview

DHNPB-0003

Development stage: Preclinical
Lead developer: Daehan Nupharm
Administration: Subcutaneous

Overview

DHNPB-0003 is a biologic drug candidate being developed by the South Korean pharmaceutical company Daehan Nupharm for the treatment of Hepatitis B Virus (HBV) infection. Currently in the preclinical stage, DHNPB-0003 is part of Daehan Nupharm's expanding portfolio of biological therapeutics. While specific details regarding its mechanism of action—such as whether it is a monoclonal antibody, a recombinant protein, or a therapeutic vaccine—are not publicly available, the candidate is designed to target HBV to address the needs of patients with chronic infections.

Beyond the preview

Go deeper on DHNPB-0003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHNPB-0003.

Explore the full profile